4553 — Towa Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Towa Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	154,900	165,615	208,859	227,934	259,594
Cost of Revenue
Gross Profit	65,452	70,186	72,714	81,383	94,729
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	137,411	144,103	205,685	204,980	235,144
Operating Profit	17,489	21,512	3,174	22,954	24,450
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,728	22,246	4,605	24,459	26,330
Provision for Income Taxes
Net Income After Taxes	13,958	15,915	2,201	16,173	18,987
Net Income Before Extraordinary Items
Net Income	13,958	15,915	2,201	16,173	18,987
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	13,944	15,912	2,201	16,173	18,986
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	321	298	172	340	454
Dividends per Share
Special Dividends per Share